The Next Wave In Cancer Treatment - Kinase InhibitorsDocument Transcript
The Next Wave In Cancer Treatment - Kinase InhibitorsReport Details:Published:December 2012No. of Pages: 160Price: Single User License – US$2500This Kalorama Information report – The Next Wave in Cancer Treatment--Kinase Inhibitors - isfocused on a growing area of cancer treatment, kinase inhibitors. Several cancers are beingtreated with these newer therapies, which provide a focus of cancer profiled in this report,including:•Breast•Colorectal•Head/Neck•Kidney•Leukemia•Liver•Lung•Melanoma•Ovarian•Pancreatic•Prostate•StomachThe report covers both currently marketed and late stage development kinase inhibitors for cancertreatment. Revenues for this market segment were generated using dollar and unit sales for eachproduct.The report includes statistical information for relevant cancers by type worldwide, with specialemphasis on the U.S. market. Specifically, cancers where there are current products available orare in development are profiled. The market segments provide an overview, description of kinaseinhibitors currently on the market, leading product sales, market estimates and forecasts, andcompetitive analysis of leading providers. The report also includes a list of products indevelopment and current issues and trends affecting the cancer industry as a whole.The information for this report was gathered using both primary and secondary research includingcomprehensive research of secondary sources such as company literature, databases, investmentreports, and medical and business journals. Telephone interviews and email correspondence werethe primary method of gathering information. For the purpose of this study Kalorama Informationconducted interviews with key industry officials, consultants, health care providers, andgovernment personnel. These sources were the primary basis in gathering information specifically
relating to revenue and market share data presented in this report. Specific interviews withpharmaceutical company representatives included marketing directors, division managers, andproduct representatives.All market data pertains to the world market at the manufacturers’ level. The base year for datawas 2012. Historical data was provided for the years 2007 through 2011, with forecast dataprovided for 2013 through 2017. Compound annual growth rates (CAGRs) are provided for the2007-2012, 2012-2017 and 2007-2017 periods for each industry segment covered. Competitiveanalysis is provided for the year 2012. The forecasted market analysis for 2013-2017 was basedon probability of approval and sales of products in late stage development, competitive trends,product marketing, and demographic trends.The market for kinase inhibitors is heating up. The newer segment has shown strong growththroughout the 2000s with average annual increases of nearly 17%. Although the market isbecoming more established and several billion dollar drugs have emerged this segment hasenormous room for growth. The potential market is expected to grow to reach almost $20 billionworldwide within the next five years. Several factors continue to influence the double-digit growththis market has experienced, including the continued success of targeted therapy in cancertreatment, rising incidence of cancer, and increased cost for newly approved therapies in theadvanced treatment area.This market report only includes estimates and forecasts for the kinase inhibitor market for cancerindications. For a complete report on the cancer segment see Kalorama Information report CancerTherapeutics and for an in-depth look at the new cancer vaccine segment see KaloramaInformation report Emerging Cancer Vaccines: Market Forecasts, New Developments and PipelineAnalysis.Get your copy of this report @http://www.reportsnreports.com/reports/213315-the-next-wave-in-cancer-treatment-kinase-inhibitors.htmlMajor points covered in Table of Contents of this report includeTABLE OF CONTENTSCHAPTER ONE: EXECUTIVE SUMMARYIntroductionScope and MethodologyTyrosine Kinase Inhibitors (TKIs) MarketSize and Growth of the MarketIssues and Trends Affecting MarketLeading CompetitorsCHAPTER TWO: INTRODUCTIONWhat is Cancer?Biochemistry of Cancer CellsCarcinogen MetabolismCauses of Cancer GrowthEnvironmental Factors, DNA, RNACellular Oncogenes
Tumor Suppressor GenesHistory and Growth of the Cancer Treatment MarketIndustry StructureDemographics and StatisticsGlobal Cancer StatisticsLung CancerBreast CancerColon/Rectal CancerCancer Stats in the United StatesDemographicsAging PopulationLife Expectancy and CancerLife ExpectancyBirth RatesDescription of Select CancersBreast CancerColorectal CancerHead and NeckKidneyLeukemiaLiverLung CancerMelanomaOvarian CancerPancreasProstate CancerStomach CancerCHAPTER THREE: PRODUCTSOverviewBosulif (bosutinib)Caprelsa (vandetanib)Gleevec (imatinib)Inlyta (axitinib)Iressa (gefitinib)Jakafi (ruxolitinib)Nexavar (sorafenib)Sprycel (dasatinib)Stivarga (regorafenib)Sutent (sunitinib)Tarceva (erlotinib)Tasigna (nilotinib)Tyverb/Tykerb (lapatinib)
Votrient (pazopanib)Xalkori (crizotinib)Zelboraf (vemurafenib)CHAPTER FOUR: MARKET SIZE AND GROWTHMarket SummaryMarkets by Geographical SegmentsU.S. MarketEurope MarketJapan MarketROW MarketCompetitive AnalysisCHAPTER FIVE: NEW DEVELOPMENTSThe Pipeline for Kinase InhibitorsSignificant DevelopmentsAfatinibAxitinibBosutinibCabozantinibCrizotinibMotesanibPonatinibRegorafenibTivozanibRecent NDA ActivityNew ApprovalsPatent Activity and Generic DevelopmentCHAPTER SIX: ISSUES AND TRENDSIntroductionInsurance and Reimbursement IssuesPersonalized MedicineTargeted Cancer TherapyPharmacogenomicsAlliances Acquisitions and Licensing AgreementsAmgenAstellasAstraZenecaBristol-Myers SquibbEli Lilly & Co.Johnson & JohnsonMerckNovartisPfizer
Patient-Reported OutcomesHealthy Lifestyles Continue to Show Promise for Cancer PreventionObesity in the U.S.U.S. Obesity Rates Differ Among Ethnic GroupsAlcohol’s Affect on Cancer IncidenceMarketing and Distribution TrendsGeographical TrendsUnited StatesEuropeJapanElderly Clinical Trial InvolvementCHAPTER SEVEN:COMPANY PROFILESIntroductionAstraZeneca plcBayerBristol-Myers Squibb CompanyGlaxoSmithKlineNovartisPfizer, Inc.RocheAPPENDIX:MAJOR COMPETITORS’ ADDRESSESCHAPTER ONE: EXECUTIVE SUMMARYFigure 1-1: Sales of Kinase Inhibitor Products, 2012Figure 1-2: World Cancer Kinase Inhibitor Market, 2007-2017Table 1-1: World Cancer Kinase Inhibitor Market, 2007-2017Figure 1-1: World Cancer Kinase Inhibitor Market, 2007-2017 w/ Growth TrendCHAPTER TWO: INTRODUCTIONTable 2-1: Viruses Associated with Cancer in HumansFigure 2-1: Approved Cancer Therapies in the United States byPrimary IndicationFigure 2-2: Approved Kinase Inhibitors for Cancer Treatmentin the United States by Original Indication*Table 2-2: Total Cancer Incidence by Gender and Country, 2010 EstimatesFigure 2-3: Cancer Incidence by Gender and Country, 2010 EstimatesTable 2-3: World Cancer Incidence by Selected Types of Cancer, 2010 and2020, all races, both gendersFigure 2-4: Estimated and Projected World Cancer Incidence bySelected Types of Cancer, 2010 and 2020Table 2-4: Most Common Cancer by Region and GenderTable 2-5: United States: Total Cancer Incidence by Gender, 2012 EstimatesFigure 2-5: United States: Total Cancer Incidence by Gender, 2012 EstimatesTable 2-6: United States: Total Cancer Deaths by Gender, 2012 Estimates
Figure 2-6: United States: Total Cancer Deaths by Gender, 2012 EstimatesTable 2-7: World Population by Selected Geographical Region, 2010 - 2050Figure 2-7: World Population by Selected Geographical Region, 2010–2050Table 2-8: Percent Population Over 65 by Year and Region, 2010-2050Figure 2-8: Estimated World Population by Age, 2010 and 2050Table 2-9: Average Life Expectancy in Years by Country 1980 and 2011Figure 2-9: Average Life Expectancy in Years by Country 1980 and 2011Table 2-10: United States Average Years of Life Lost Per Person Dying ofCancer, All Races, Both Sexes, 2009Table 2-11: United States Estimated Person-Years of Life Lost Due toCancer, All Races, Both Sexes, 2009Table 2-10: Crude Birth Rate per 1,000 Persons 2000, 2005 and 2010Figure 2-12: Crude Birth Rate per 1,000 Persons 2000, 2005 and 2010Table 2-11: Types of LeukemiaTable 2-12: Types of Primary Lung CancerTable 2-13: Malignant Conditions of the SkinCHAPTER THREE: PRODUCTSTable 3-1: Cancer Indicated Kinase Inhibitor Approvals by YearFigure 3-1: Table 3-2: Leading Products by Sales, 2010 and 2012CHAPTER FOUR: MARKET SIZE AND GROWTHTable 4-1: World Cancer Kinase Inhibitor Market, 2007-2017Figure 4-1: World Cancer Kinase Inhibitor Market, 2007-2017Table 4-2: World Cancer Kinase Inhibitor MarketFigure 4-2: World Cancer Kinase Inhibitors MarketTable 4-3: U.S. Kinase Inhibitor Products by Sales, 2012Figure 4-3: U.S. Kinase Inhibitor Products by Sales, 2012Table 4-4: Europe Kinase Inhibitor Products by Sales, 2012Figure 4-4: Europe Kinase Inhibitor Products by Sales, 2012Figure 4-5: World Cancer Kinase Inhibitor MarketFigure 4-6: World Cancer Kinase Inhibitor MarketFigure 4-7: World Cancer Kinase Inhibitor MarketTable 4-5: Top 5 Suppliers: Cancer Kinase Inhibitor Market – Sharesby Market Revenues, 2012Figure 4-8: Top 5 Suppliers: Cancer Kinase Inhibitor Market – Sharesby Market Revenues, 2012CHAPTER FIVE: NEW DEVELOPMENTSTable 5-1: Developments in Kinase Inhibitors, Selected ProjectsFigure 5-1: Registration and Phase III Compounds in Development for MajorIndications, Distribution EstimatesTable 5-2: Recent NDA Activity: January 2011-October 2012Table 5-3: Select New Approvals (NCE, Indications, Dosage, Formulations)January 2010-October 2012
Table 5-4: Patent Data for Kinase InhibitorsCHAPTER SIX: ISSUES AND TRENDS AFFECTING THE CANCER MARKETTable 6-1: Obesity Rates by U.S. State, 2011CHAPTER SEVEN: COMPANY PROFILESFigure 7-1: Cancer Kinase Inhibitor Development for Leading CompaniesContact: email@example.com for more information.